Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine Addition in Carpal Tunnel Release
NCT04833777Completed
- Sponsor
- University of Saskatchewan
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine in carpal tunnel syndrome (CTS) (2 arms), sponsored by University of Saskatchewan. Primary endpoints: Post-operative Pain (Visual Analog Scale) at 24 hours and Post-operative Analgesia Requirements at 72 hours. Started Jul 2021; status: completed.
02
Drugs
bupivacaine
03
Conditions
carpal tunnel syndrome (CTS)
Beyond the preview
Go deeper on NCT04833777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833777.